GlassScriptPhysician profile
Sara B Oreilly
NPI 1063623205
$2,434.56
in general payments reported to CMS, 2019-2025
27 companies · $400 in 2025
The $400 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $638 · 2021: $48.79 · 2022: $778 · 2023: $171 · 2024: $140 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653 · Education: $58.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.49 |
| Education | $58.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $1,264.00 | 2019-2022 | |
| Hologic Sales and Service, LLC | $155.68 | 2022-2025 | Myosure Tissue Removal Device, Fluent Fluid Management System, Aptima |
| Astellas Pharma US INC | $153.05 | 2024-2025 | Veozah |
| Mayne Pharma Commercial LLC | $144.12 | 2021-2025 | |
| Abbvie INC. | $105.87 | 2019-2023 | |
| Exeltis, USA INC. | $82.00 | 2019-2025 | Slynd |
| Organon LLC | $59.63 | 2023-2025 | Jada System |
| Millicent US INC | $58.35 | 2023-2025 | Femring |
| Pfizer INC. | $52.16 | 2022-2025 | |
| Coopersurgical, INC. | $36.29 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Therapeuticsmd, INC. | $35.77 | 2021-2022 | |
| Amgen INC. | $29.94 | 2019-2025 | Evenity, Prolia |
| Avion Pharmaceuticals | $29.27 | 2022-2023 | Balcoltra |
| Allergan, INC. | $27.75 | 2019 | |
| Daiichi Sankyo INC. | $26.72 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dysis Medical, INC. | $19.79 | 2022 | |
| Olympus America INC. | $19.54 | 2023 | Endoeye Flex 3d Deflectable Videoscope |
| Incyte Corporation | $19.00 | 2025 | Monjuvi, Zynyz |
| Evofem Biosciences, INC. | $17.00 | 2025 | Phexxi, Solosec, Phexx |
| Roche Diagnostics Corporation | $16.71 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.00 | 2019 | |
| Agile Therapeutics, INC. | $15.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.22 | 2019 | |
| Merck Sharp & Dohme LLC | $14.11 | 2024 | Gardasil 9, Gardasil |
| Lupin INC. | $12.50 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Oreilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.